New Avenues in Antihypertensive Drug Treatment

References

• Medical Research Council Working Party. MRC-trial of mild hypertension. Brit. Med. J. 1985; 291: 97–104
   PubMed Web of Science ®Google Scholar
• Mac Mahon S, Peto R, Cutler J. Blood pressure, stroke and coronary heart disease. Part 1. Lancet 1990; 335: 765–764
   PubMed Web of Science ®Google Scholar
• Collins R, Peto R, MacMahon S. Blood pressure, stroke and heart disease. Part 2. Lancet 1990; 335: 827–838
   PubMed Web of Science ®Google Scholar
• Sever P. 1985—The year of hypertension trials: interpreting the results. Trends Pharmacol. Sci. 1986; 6: 134–139
   Web of Science ®Google Scholar
• SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program (SHEP). JAMA 1991; 265: 3255–3264
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Lindholm LH, Hansson L. Morbidity and mortality in Swedish Trial in Old Patients with Hypertension (STOP-Hypertension. Lancet 1991; 338: 1281–1285
   PubMed Web of Science ®Google Scholar
• MRC Working Party. Medical research council trial of hypertension in older adults: principal results. Br. Med. J. 1992; 304: 405–412
   PubMed Web of Science ®Google Scholar
• VanZwieten PA. Vascular effects of calcium antagonists: implications for hypertension and other risk factors for coronary heart disease. Am. J. Cardiol. 1989; 64: 1171–1211
   Web of Science ®Google Scholar
• Opie LH. Clinical use of calcium antagonist drugs. Kluwer Acad. Publ., Boston 1990; 1–326
   Google Scholar
• Schwartz A, van Zwieten P A. Pharmacologic and therapeutic considerations of amlodipine, a new 1,4-dihydropyridine calcium antagonist. Am. J. Cardiol 1989; 64: 11–1371
   PubMed Web of Science ®Google Scholar
• Van Zwieten PA. Cardiovascular drug therapy; what is new? Calcium antagonists. Neth. J. Cardiol. 1992; 5: 17–22
   Google Scholar
• Henry PD. Calcium channel blockers and progression of coronary artery disease. Circulation 1990; 82: 2251–2253
   PubMed Web of Science ®Google Scholar
• Brogden RM, Todd PA, Sorkin E M. Captopril: an update of its pharmacodynamic and pharmacokinetic use in hypertension and congestive heart failure. Drugs 1988; 36: 540–600
   PubMed Web of Science ®Google Scholar
• Mac Areavery M, Robertson J IS. Angiotensin converting enzyme inhibitors and moderate hypertension. Drugs 1990; 40(suppl. 3)326–345
   PubMed Web of Science ®Google Scholar
• Lees KR, Reid J L. Haemodynamic and humoral effects of oral perindopril, an angiotensin converting enzyme inhibitor, in man. Br. J. Clin. Pharmacol. 1987; 23: 159–164
   PubMed Web of Science ®Google Scholar
• Asmar RG, Journo HJ, Lacolley PJ, Santoni JP, Billaud E, Levy B, Safar M E. Treatment for one year with perindopril: effect on cardiac mass and arterial compliance in essential hypertension. J. Hypertension 1988; 6(suppl. 3)S33–S39
   PubMedGoogle Scholar
• Todd PA, Benfield Ramipril P. A review of its pharmacological properties and therapeutic efficay in cardiovascular disorders. Drugs 1990; 39: 110–135
   PubMed Web of Science ®Google Scholar
• Van Zwieten PA. Role of adrenoceptors in circulatory and metabolic regulation. Am. Heart J. 1988; 116: 1384–1392
   PubMed Web of Science ®Google Scholar
• Van Zwieten PA. Drugs interacting with alpha-adrenoceptors. Cardiovasc. Drugs Ther. 1989; 3: 121–133
   PubMed Web of Science ®Google Scholar
• Bricca C, Dontenwill M, Molines A, Feldman J, Belcourt A, Bousquet P. The imidazoline preferring receptor: binding studies in bovine, rat and human brain stem. Eur. J. Pharmacol. 1989; 162: 1–9
   PubMed Web of Science ®Google Scholar
• Tibirica E, Feldman J, Mermet O, Gonon F, Bousquet P. An imidazoline-specific mechanism for the hypotensive effect of clonidine: a study with yohimbine and idazoxan. J. Pharmacol. exp. Ther. 1991; 256: 606–613
   PubMed Web of Science ®Google Scholar
• Chrisp P, Faulds D. Moxonidine. A review of its pharmacology and therapeutic use in essential hypertension. Drugs 1992; 44: 993–1012
   PubMed Web of Science ®Google Scholar
• Van Nueten JM, Janssen P AJ, Symoens Ketanserin J. New cardiovascular drugs. Raven Press, New York 1987; 1–56
   Google Scholar
• Van Zwieten PA, Blauw GJ, van Brummelen P. Serotonergic receptors and drugs in hypertension. Pharmacol. Toxicol. 1992; 70: S17–S22
   PubMedGoogle Scholar
• Van den Meiracker AH, Admiraal P JJ. Prolonged blood pressure reduction by the orally active renin inhibitor RO-42–5892 in essential hypertension. Br. Med. J. 1990; 301: 205–210
   PubMed Web of Science ®Google Scholar
• Timmermans P BM, Wong PC, Chin AT, Herblin W F. Nonpeptide angiotensin II-receptor antagonists. Trends Pharmacol. Sci. 1991; 12: 55–59
   PubMed Web of Science ®Google Scholar
• Timmermans P BM, Carini DJ, Chin AT, Duncia JV, Price WA, Wells GJ, Wong PC, Wexler RR, Johnson A L. Angiotensin II-receptor antagonists. From discovery to antihypertensive drugs. Hypertension 1991; 18(suppl. III)136–142
   Google Scholar
• Louis WJ, McNeill J, Labetalol J., Doyle AE. Handbook of Hypertension, vol. 5. Elsevier, Amsterdam 1984; 225–245
   Google Scholar
• Van Zwieten PA. Hybrid or multifactorial drugs in antihypertensive treatment. J. Hypertension 1990; 8: 687–696
   PubMed Web of Science ®Google Scholar
• Schoetensack W, Bruckschen EG, Zech K. Urapidil. New Drugs Annual: Cardiovascular Drugs, A Scriabine. Raven Press, New York 1983; 19–48
   Google Scholar
• Van Zwieten PA. Pharmacologic and therapeutic aspects of urapidil. Am. J. Cardiol. 1989; 64: 1D–39D
   PubMed Web of Science ®Google Scholar
• Ruffolo RR, Sulpizio AC, Nichols AJ, De Marinis RM, Hieble J P. Pharmacological differentiation between pre- and postjunctional a2-adrenoceptors by SK&F 104078. Naunyn-Schmiedeberg's Arch. Pharmacol. 1987; 336: 415–418
   Google Scholar
• Sanguinetti MC. Modulation of potassium channels by antiarrhythmic and antihypertensive drugs. Hypertension 1992; 19: 228–236
   PubMed Web of Science ®Google Scholar
• Häusler G. K+-channels openers: new antihypertensive drugs?. Clin. Physiol. Biochem. 1990; 8(suppl. 2)46–56
   PubMedGoogle Scholar
• Seymour AA, Monnan JA, Asaad MM, Fennel SA, Little DK, Kratunis VJ, Lynn Rogers W. Antihypertensive and renal activity of SQ 28,603, an inhibitor of neutral endopeptidase. J. Cardiovasc. Pharmacol. 1991; 17: 296–304
   PubMed Web of Science ®Google Scholar
• Lefrancois P, Clerc G, Duchier J, Lim C, Lecomte JM, Gros C, Schwartz J C. Antihypertensive activity of sinorphan. Lancet 1990; 336: 307–308
   PubMed Web of Science ®Google Scholar